BioGeometry and Sanyou Bio have announced a strategic partnership to advance drug research and development. BioGeometry, known for its AI-driven protein design, and Sanyou Bio, a leader in innovative biologic drug R&D, will utilize their strengths in generative AI and drug development to create a next-generation antibody discovery platform.

生物几何和三友生物宣布建立战略合作伙伴关系，以推进药物研究和开发。以人工智能驱动的蛋白质设计而闻名的生物地理学和创新生物药物研发的领导者三友生物将利用其在生成人工智能和药物开发方面的优势，创建下一代抗体发现平台。

This collaboration aims to foster cooperation with leading pharmaceutical companies, enhancing global competitiveness.Sanyou Bio will integrate BioGeometry's generative AI antibody design platform, GeoBiologics, into its operations. Both companies will pool their resources, technologies, and expertise to develop an advanced Dry-Wet antibody R&D platform.

这种合作旨在促进与领先制药公司的合作，增强全球竞争力。三友生物将把生物地理学的生成性人工智能抗体设计平台GeoBiologics整合到其运营中。两家公司将汇集他们的资源、技术和专业知识，开发一个先进的干湿抗体研发平台。

This will combine BioGeometry's AI algorithms with Sanyou Bio's laboratory capabilities, facilitating the development of large molecule drugs and innovative projects.Sanyou Bio has established a high-throughput R&D platform for antibody drugs, featuring the world's largest antibody library with a capacity of up to 10 trillion.

这将结合生物地理学的人工智能算法和三友生物的实验室能力，促进大分子药物和创新项目的开发。三友生物建立了抗体药物高通量研发平台，拥有全球最大的抗体库，容量高达10万亿。

This platform integrates phage display and mammalian cell protein expression technologies, along with fully automated screening and R&D capabilities. It is designed to address challenging targets and develop high-affinity, highly developable molecules.BioGeometry has developed atomic-level geometric deep learning models that accelerate antibody design and reduce costs.

该平台集成了噬菌体展示和哺乳动物细胞蛋白表达技术，以及全自动筛选和研发能力。它旨在解决具有挑战性的目标，并开发高亲和力，高度可开发的分子。生物地理学已经开发出原子级几何深度学习模型，可以加速抗体设计并降低成本。

Their generative AI antibody discovery SaaS platform, GeoBiologics, combines AI design with high-throughput laboratory validation, enhancing prediction accuracy and efficiency through iterative AI and experimental feedback.Sanyou Bio, stated, 'BioGeometry's AI technology has revolutionized our antibody drug R&D platform, enhancing our drug discovery capabilities.

。三友生物表示，“生物几何的人工智能技术彻底改变了我们的抗体药物研发平台，增强了我们的药物发现能力。

Our collaboration with BioGeometr.

我们与BioGeometr的合作。